At a Glance
| Full name | High-grade serous carcinoma (HGSC) |
| Cancer family | Epithelial ovarian/fallopian tube cancer |
| Share of ovarian cancer cases | Approximately 70–80% of epithelial tumours |
| Typical age at diagnosis | 55–70 years (median around 63) |
| Characteristic genetic change | TP53 mutation (found in more than 95% of tumours) |
| Hereditary link | BRCA1/BRCA2 mutations in roughly 20–25% of cases |
| Most common stage at diagnosis | Stage III or IV (advanced) |
| Main treatments | Surgery, platinum-based chemotherapy, PARP inhibitors, bevacizumab |
| Blood marker used | CA-125 (often combined with HE4) |
What Is High-Grade Serous Carcinoma?
High-grade serous carcinoma (HGSC) is the most common — and most aggressive — form of ovarian cancer. It develops from the epithelial cells that line the ovary and fallopian tube and belongs to a wider group called epithelial ovarian cancers, so named because they arise from epithelium, the thin layer of cells covering organs.
Two features define this disease:
- “Serous” describes the appearance and behaviour of the cancer cells, which resemble the lining of the fallopian tube.
- “High-grade” means the cells look highly abnormal under the microscope and divide rapidly, reflecting fast, aggressive growth.
Importantly, modern research has reshaped how doctors think about where this cancer starts. Although it was historically labelled “ovarian cancer,” strong evidence now shows that most HGSC tumours actually begin in the fallopian tube, particularly in the fimbriae — the delicate fringes at the end of the tube nearest the ovary. For this reason, HGSC of the ovary, the fallopian tube, and the lining of the abdomen (peritoneum) are now regarded as one and the same disease, treated identically and often called “tubo-ovarian high-grade serous carcinoma.”
HGSC is sometimes described as a “silent” cancer because early tumours rarely cause clear symptoms. Around three out of four women are diagnosed at an advanced stage, once the cancer has already spread within the abdominal cavity. Even so, outcomes have improved meaningfully in recent years thanks to better surgery, modern chemotherapy, and a newer class of targeted drugs called PARP inhibitors.
Where Does the Cancer Begin? Understanding Its Origin
The discovery of where HGSC truly originates is one of the most important advances in gynaecological cancer research over the past two decades.
When surgeons removed the ovaries and fallopian tubes of healthy women carrying BRCA1 or BRCA2 mutations (to lower their cancer risk), pathologists examined the tissue closely and found something unexpected: tiny, hidden, pre-cancerous changes in the fimbriated end of the fallopian tube — not in the ovary at all.
These early lesions are called serous tubal intraepithelial carcinoma (STIC). They carry the same TP53 gene mutation found in full-blown HGSC tumours, establishing them as the likely precursor. The currently accepted chain of events is:
- Early damage: Fallopian tube secretory cells acquire genetic damage, beginning with a “p53 signature” — cells with a TP53 mutation that still look normal.
- Formation of STIC: These damaged cells progress into a thin layer of frankly malignant cells confined to the tube lining.
- Spread to the ovary and abdomen: Because the tube opens directly into the abdominal cavity, cancer cells can shed and float free, implanting on the ovary, the peritoneum, and the omentum (a fatty sheet of tissue in the abdomen).
This model elegantly explains two long-standing puzzles:
- Why HGSC is so often diagnosed late — the primary tumour can remain microscopic while shed cells are already spreading.
- Why some women have widespread abdominal disease with normal-looking ovaries — in these cases the tumour may be classified as primary peritoneal HGSC, but it is the same disease biologically.
Who Is Affected? Epidemiology
Ovarian cancer is the eighth most common cancer in women worldwide, with approximately 313,000 new cases and over 207,000 deaths recorded globally in 2020. HGSC accounts for the majority of both cases and deaths, making it the principal driver of ovarian cancer mortality.
Key epidemiological patterns include:
- Age: Risk rises sharply after the menopause; most cases are diagnosed between the ages of 55 and 70.
- Geography: Incidence is highest in high-income countries, although mortality gaps partly reflect differences in access to specialist care.
- Trends: Rates have declined modestly in some regions — likely due to widespread use of oral contraceptives and increasing preventive surgery in women at high genetic risk.
Causes and Risk Factors
The exact cause of HGSC in any individual woman is usually unknown. Like most cancers, it results from accumulated genetic damage, and the overwhelming hallmark is a faulty TP53 gene — the “guardian of the genome” that normally prevents damaged cells from multiplying.
Known risk and protective factors
| Factors that increase risk | Factors that reduce risk |
|---|---|
| Inherited BRCA1/BRCA2 mutations | Use of the combined oral contraceptive pill (protection increases with years of use) |
| Other inherited DNA-repair gene faults (RAD51C, RAD51D, BRIP1, PALB2, Lynch syndrome) | Pregnancy and breastfeeding |
| Increasing age, especially after menopause | Tubal ligation (sterilisation) |
| Never having been pregnant (nulliparity) | Removal of the fallopian tubes and ovaries (risk-reducing surgery) |
| Family history of ovarian, breast, bowel, or pancreatic cancer | Hysterectomy |
| Postmenopausal hormone therapy (modest effect) | |
| Obesity | |
| Possibly long-term talc use on the perineum (evidence debated) |
A crucial point: Most women who develop HGSC have no identifiable risk factor at all**. Everyone with ovaries and fallopian tubes can potentially develop this disease, which is why knowing the symptoms matters for everyone.
Inherited Risk and Genetic Testing
Approximately one in four to five HGSC cases is linked to an inherited fault in a DNA-repair gene — most commonly BRCA1 or BRCA2:
- BRCA1 carriers: lifetime ovarian cancer risk of roughly 35–45%
- BRCA2 carriers: lifetime risk of roughly 10–20%
Because of this strong link, current international guidelines recommend that every woman diagnosed with HGSC is offered genetic testing, regardless of family history. The results matter for three reasons:
- Treatment: Patients with BRCA mutations — or tumours with a related defect called homologous recombination deficiency (HRD) — respond particularly well to PARP inhibitor maintenance therapy.
- Family protection: Relatives can be tested and, if affected, offered risk-reducing options such as removal of the tubes and ovaries after completing their family.
- Future planning: Results may influence surgical choices (for example, management of the unaffected breast in carriers).
How Does It Look?
HGSC has a characteristic appearance at every level — on scans, in the operating theatre, and under the microscope. Understanding these appearances also helps explain how the disease behaves.
Appearance on Imaging
Before surgery, CT scans and ultrasounds typically reveal:
- Complex adnexal masses — ovarian tumours that are part solid and part cystic, often with irregular walls and internal growths.
- Ascites — significant free fluid in the abdomen and pelvis.
- Peritoneal thickening and nodules — the lining of the abdomen appears studded or thickened.
- “Omental caking” — the omentum is replaced by a dense sheet of tumour, one of the most recognisable radiological signs of advanced HGSC.
- Enlarged lymph nodes in the pelvis or abdomen.
Appearance to the Surgeon (Macroscopic)
At operation, the typical findings include:
- Bilateral ovarian masses: Both ovaries are involved in roughly 40–60% of cases. The tumours are usually solid and cystic, grey-white, soft, and friable (crumbly), frequently containing areas of bleeding and dead tissue (necrosis).
- Papillary growths: Frond-like, cauliflower-shaped projections grow into cyst spaces and onto the surface of the ovary. Surface involvement signals a higher likelihood of spread.
- A “salt-and-pepper” abdomen: The peritoneum may be covered with hundreds or thousands of tiny tumour seedlings (peritoneal carcinomatosis), feeling gritty or nodular to the examining surgeon.
- Ascites: Often several litres of clear or blood-stained fluid accumulate in the abdomen.
- Omental cake: The omentum becomes thick, rigid, and infiltrated with tumour.
- Deceptively small primary sites: In some women, the ovaries and tubes look almost normal even though the abdomen contains widespread disease — strong evidence of the tubal origin described earlier.
Appearance Under the Microscope (Histology)
Pathologists diagnose HGSC by examining tumour tissue at high magnification. Characteristic features include:
- Disordered architecture: Cells grow in papillary fronds, solid sheets, and abnormal gland-like clusters, often separated by slit-like spaces.
- Highly abnormal cells (“high grade”): The cell nuclei are dramatically enlarged, irregular, variable in size and shape (pleomorphic), and darkly staining (hyperchromatic), with prominent nucleoli.
- Rapid division: There are very high numbers of cells in the process of dividing (mitoses), including abnormal forms — a direct reflection of the tumour’s speed of growth.
- Necrosis: Patches of dead tumour are common because growth outpaces the blood supply.
- Psammoma bodies: Concentrically layered, chalky calcifications may be present, though they are less prominent than in low-grade serous tumours.
The Immunohistochemical Fingerprint
Pathologists confirm the diagnosis with immunohistochemistry (IHC) — staining the tumour for specific proteins. HGSC has a distinctive profile:
| Marker | Result in HGSC | What it tells us |
|---|---|---|
| PAX8 | Positive | Confirms Müllerian (tubal/ovarian) origin |
| WT1 | Positive (nuclear staining) | Typical of serous carcinoma |
| p53 | Abnormal — either intense staining in nearly all cells, or complete absence (“null” pattern) | Reflects the underlying TP53 mutation |
| p16 | Strongly positive (block staining) | Supports high-grade biology |
| Ki-67 | High (often 30–70%+) | Confirms rapid proliferation |
HGSC vs. Low-Grade Serous Carcinoma — Two Different Diseases
An important modern insight is that high-grade and low-grade serous carcinomas are not simply mild and severe versions of one disease — they are biologically distinct:
| Feature | High-grade serous carcinoma | Low-grade serous carcinoma |
|---|---|---|
| Origin | Fallopian tube (STIC) | Ovarian surface / borderline tumours |
| Key mutations | TP53 (>95%) | KRAS, BRAF, NRAS |
| Growth rate | Rapid | Slow |
| p53 staining | Abnormal | Normal (wild-type) |
| Platinum chemotherapy | Usually very sensitive initially | Often relatively resistant |
| Typical behaviour | Aggressive, early spread | Indolent but persistent |
This distinction changes treatment choices, which is why precise pathological classification matters so much.
Symptoms
HGSC is often called a “silent killer,” but this is misleading: research shows that most women do experience symptoms before diagnosis. The problem is that the symptoms are vague, non-specific, and easily mistaken for common, harmless conditions such as irritable bowel syndrome, urinary infections, menopause, or simple ageing. The key is recognising when symptoms are new, persistent, and worsening.
The Four Most Common Symptoms
- Persistent abdominal bloating or swelling
Not the normal bloating that comes and goes with meals or the menstrual cycle — this bloating does not go away. Waistbands and clothes become progressively tighter, and the abdomen may visibly enlarge.
- Pelvic or abdominal pain
A persistent ache, pressure, discomfort, or feeling of heaviness in the lower abdomen or pelvis.
- Feeling full quickly or loss of appetite
Called early satiety — feeling full after only a few mouthfuls, losing interest in food, or experiencing unexplained nausea.
- Urinary urgency or frequency
Needing to pass urine more often, or more urgently, than usual — even without drinking more fluids.
Other Possible Symptoms
- Unexplained weight loss (or weight gain from fluid build-up)
- Visible abdominal swelling due to ascites (accumulated fluid)
- Persistent fatigue or low energy
- Changes in bowel habit, particularly new constipation
- Indigestion, heartburn, or nausea that does not settle
- Pain during sexual intercourse (dyspareunia)
- Abnormal vaginal bleeding, including bleeding after the menopause (less common, but always needs checking)
- Lower back pain
- Shortness of breath — in advanced disease, this may indicate fluid around the lungs (pleural effusion)
- Leg swelling, due to pressure on lymphatic vessels or, rarely, a blood clot
Why Symptoms Are Missed
The pattern of HGSC symptoms explains the frequent delays in diagnosis:
- They are common sensations experienced by healthy people every day.
- They often appear gradually over weeks to months.
- They are readily attributed to digestive problems — studies show many women are investigated for bowel disorders before ovarian cancer is considered.
When to See a Doctor
⚠️ Seek medical advice promptly if you experience symptoms that are: – Persistent — occurring more or less daily – Frequent — more than about 12 times per month – New — unusual for you – Worsening — gradually becoming more pronounced This is especially important if you are over 50 or have a family history of ovarian or breast cancer. Most women with these symptoms will not have cancer — but the combination of persistence and progression always deserves investigation, and you should not wait for symptoms to “settle on their own” beyond two to three weeks.
How Is HGSC Diagnosed?
There is no single test for HGSC. Diagnosis usually follows a stepwise pathway:
1. Medical History and Physical Examination
The doctor asks about symptoms, personal history, and family history of cancer, then performs abdominal and pelvic examinations to feel for masses or fluid.
2. Blood Tests (Tumour Markers)
- CA-125: Raised in around 80% of women with advanced HGSC. However, it can also be elevated by benign conditions — menstruation, endometriosis, fibroids, liver disease — so it is not suitable as a stand-alone screening test. Its greatest value lies in monitoring response to treatment and detecting recurrence.
- HE4: Often measured alongside CA-125; the two are combined with menopausal status in the ROMA score (Risk of Ovarian Malignancy Algorithm) to estimate the likelihood that a pelvic mass is malignant.
3. Imaging
| Test | Role |
|---|---|
| Transvaginal ultrasound | First-line test; characterises a pelvic mass as simple, complex, or solid |
| CT scan (abdomen, pelvis ± chest) | Standard staging scan; shows spread, omental cake, ascites, lymph nodes; guides surgical planning |
| MRI | Problem-solving when ultrasound findings are unclear |
| PET-CT | Selected cases, particularly when recurrence is suspected |
4. Tissue Diagnosis
A firm diagnosis requires microscopic examination of tumour tissue, obtained by:
- Image-guided biopsy of a peritoneal or omental mass — common when chemotherapy is planned before surgery, or
- Surgery, in which the ovaries, tubes, omentum, and biopsy samples are removed and fully analysed.
The pathologist confirms the diagnosis, grade, and subtype using the microscopic and immunohistochemical features described above.
5. Genetic and Molecular Testing
- Germline (blood) testing for BRCA1, BRCA2, and related genes — recommended for all HGSC patients.
- Tumour testing for somatic (tumour-acquired) BRCA mutations and HRD status — guides decisions about PARP inhibitor therapy.
Staging: How Far Has It Spread?
HGSC of the ovary, fallopian tube, and peritoneum is staged surgically using the FIGO system (International Federation of Gynecology and Obstetrics, updated 2014):
| Stage | Description | Approx. 5-year survival* |
|---|---|---|
| I | Cancer confined to one or both ovaries/tubes | ~85–90% |
| II | Cancer has extended to other pelvic structures (e.g., uterus, bladder, rectum) | ~65–75% |
| III | Cancer has spread to the peritoneum beyond the pelvis, and/or to retroperitoneal lymph nodes | ~30–40% |
| IV | Distant spread — cancer cells in fluid around the lungs, or deposits inside organs such as the liver or spleen, or spread outside the abdomen | ~15–20% |
Figures are population averages; an individual’s prognosis depends heavily on surgical outcome, BRCA/HRD status, response to chemotherapy, and general health.*
The most common presentation is stage III disease, underlining how early and silently HGSC spreads.
Treatment
Treatment is delivered by a multidisciplinary team — gynaecological oncologists, medical oncologists, pathologists, radiologists, specialist nurses, and geneticists — and is tailored to each patient. The three pillars are surgery, chemotherapy, and increasingly, targeted maintenance therapy.
1. Surgery: Primary Debulking
For women fit enough to undergo an operation, the standard first step is primary debulking (cytoreductive) surgery, usually including:
- Removal of the uterus and cervix (total hysterectomy)
- Removal of both ovaries and fallopian tubes (bilateral salpingo-oophorectomy)
- Removal of the omentum (omentectomy)
- Complete removal of all visible tumour in the abdomen and pelvis, which may involve stripping tumour from the peritoneum or, when necessary, removing a segment of bowel or other affected tissue
The single most important surgical goal is “complete cytoreduction” — leaving no visible disease behind. Women left with no visible (or only microscopic) residual tumour have significantly better outcomes than those with larger residual deposits.
2. Chemotherapy
The backbone of drug treatment is a combination of:
- Carboplatin (a platinum-based drug) and
- Paclitaxel (a taxane),
given intravenously, typically in six cycles, three weeks apart. In some centres, a portion of the chemotherapy may be delivered directly into the abdomen (intraperitoneal chemotherapy).
HGSC is usually highly sensitive to platinum chemotherapy initially, although resistance can develop with recurrence.
3. Neoadjuvant Chemotherapy and Interval Surgery
For women with extensive disease, poor general health, or tumours unlikely to be fully removable at the outset, the standard alternative is:
- Three cycles of carboplatin–paclitaxel first (neoadjuvant chemotherapy)
- Interval debulking surgery mid-treatment
- Completion of the remaining chemotherapy cycles
Major clinical trials have shown this strategy produces similar survival to upfront surgery while reducing surgical complications and increasing the proportion of patients who can be completely debulked.
4. Maintenance and Targeted Therapies
This is the area where treatment has improved most dramatically in recent years.
PARP inhibitors (olaparib, niraparib, rucaparib) are oral tablets that exploit a weakness in HGSC cells — their impaired DNA-repair machinery. They are now routinely used as maintenance therapy after a response to first-line chemotherapy, particularly in women with:
- A BRCA mutation (inherited or in the tumour), or
- HRD-positive tumours.
Large trials (SOLO-1, PRIMA, PAOLA-1) have shown these drugs can substantially extend the time before the cancer returns — by years rather than months in BRCA-mutated disease.
Bevacizumab is an intravenous antibody that starves tumours of their blood supply (anti-angiogenic therapy). It may be added to chemotherapy and continued as maintenance, particularly in patients with advanced disease where its benefit is greatest.
5. Treatment of Recurrence
Unfortunately, many HGSC tumours eventually recur. Management depends crucially on the platinum-free interval — the time between finishing platinum chemotherapy and relapse:
| Category | Definition | Typical approach |
|---|---|---|
| Platinum-sensitive recurrence | Relapse more than 6 months after platinum therapy | Repeat platinum-based chemotherapy ± bevacizumab; sometimes secondary debulking surgery; PARP inhibitor maintenance |
| Platinum-resistant recurrence | Relapse within 6 months | Non-platinum single agents (e.g., pegylated liposomal doxorubicin, weekly paclitaxel, gemcitabine), often combined with bevacizumab; trial participation encouraged |
| Platinum-refractory disease | Disease growing during platinum therapy | Non-platinum options, targeted agents, or best supportive care based on goals of treatment |
Early symptoms of possible recurrence deserve prompt assessment, and rising CA-125 on follow-up blood tests is often the first clue.
Follow-Up After Treatment
After completing treatment, patients enter a structured follow-up programme:
- Regular clinical reviews, usually every 3 months for the first two years, then gradually spacing out over five years.
- CA-125 blood tests at visits, watching for rising trends.
- Imaging (CT) when symptoms or blood tests suggest recurrence — and in many centres as part of routine surveillance.
- Support for ongoing issues, including menopausal symptoms (after removal of the ovaries in younger women), fatigue, neuropathy from chemotherapy, and emotional wellbeing.
Some evidence suggests that treating recurrence based on a rising CA-125 alone (before symptoms appear) does not improve overall survival, so the exact use of routine CA-125 monitoring is discussed individually — but symptoms at any time should always be reported.
Prognosis and Survival
Prognosis in HGSC depends on several factors:
- Stage at diagnosis
- Amount of tumour remaining after surgery (no visible residual disease is best)
- BRCA/HRD status — carriers of BRCA mutations often respond particularly well to platinum and PARP inhibitors
- Response to chemotherapy
- General health, fitness, and age
Overall 5-year survival for advanced HGSC is approximately 30–40%, but averages conceal huge variation. Many women — particularly those with BRCA mutations benefiting from modern maintenance therapy — live many years with well-controlled disease, and long-term remissions are increasingly reported. Survival statistics also reflect patients treated before PARP inhibitors became standard, so current outcomes are likely better than published figures suggest.
Prevention and Risk Reduction
There is no reliable screening test for HGSC in the general population — neither routine CA-125 nor ultrasound has been shown to save lives when used for screening. Prevention therefore focuses on risk reduction:
- Combined oral contraceptives reduce risk substantially with prolonged use.
- Risk-reducing salpingo-oophorectomy (RRSO) — removal of tubes and ovaries, typically between ages 35–45 for BRCA1 carriers after completing childbearing — reduces ovarian cancer risk by around 95% and also reduces overall mortality.
- Opportunistic salpingectomy — removing the fallopian tubes during another planned pelvic or abdominal operation, or instead of tubal ligation — is increasingly recommended, reflecting the tubal origin of most HGSC.
- Genetic counselling and testing for women with a significant family history, enabling informed choices about surveillance and surgery.
- General measures: maintaining a healthy weight, physical activity, and avoiding smoking support overall health, though their specific effect on HGSC risk is limited.
Living with HGSC
A diagnosis of high-grade serous carcinoma affects every aspect of life. Alongside medical treatment, many women benefit from:
- Psychological support — counselling, patient support groups, and psychological oncology services
- Management of surgical menopause — hot flushes, mood changes, and bone health may need attention after oophorectomy in younger women
- Management of treatment side effects — fatigue, chemotherapy-induced neuropathy, nausea, hair loss, and bowel changes
- Nutritional support — particularly if early satiety or bowel involvement affects eating
- Genetic counselling for relatives — adult children and siblings can consider testing
- Financial and practical support — through specialist nurses, social workers, and cancer charities
- Clinical trials — HGSC research is highly active, and participation offers access to new therapies while advancing care for future patients
Specialist gynaecological oncology nurses are often the most valuable single point of contact for coordinating this support.
Questions to Ask Your Medical Team
- What stage is my cancer, and where exactly has it spread?
- Is my tumour suitable for upfront surgery, or is chemotherapy first a better option?
- Should I have genetic testing, and what will the results mean for me and my family?
- Is my tumour HRD-positive, and am I eligible for a PARP inhibitor?
- Should bevacizumab be part of my treatment?
- What side effects should I expect, and how will they be managed?
- What is the goal of treatment at each stage — cure, long-term control, or symptom relief?
- Who do I contact if I develop new symptoms between appointments?
Key Points to Remember
- HGSC is the most common and aggressive form of ovarian cancer, and scientists now believe most cases begin in the fallopian tube, not the ovary.
- Early disease usually causes no clear symptoms; persistent bloating, pelvic pain, feeling full quickly, and urinary urgency that are new and worsening should always be checked.
- Diagnosis combines examination, CA-125 blood tests, imaging, biopsy, and expert pathology, with a characteristic microscopical and immunohistochemical signature.
- Standard treatment is surgery plus platinum-based chemotherapy, increasingly followed by PARP inhibitor maintenance — which has transformed outcomes, especially for BRCA-mutated and HRD-positive disease.
- Every woman diagnosed should be offered genetic testing.
- Outcomes are improving, and active research continues to expand treatment options.
References
- Bowtell, D.D., Böhm, S., Ahmed, A.A. et al. (2015) ‘Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer’, Nature Reviews Cancer, 15(11), pp. 668–679.
- Burger, R.A., Brady, M.F., Bookman, M.A. et al. (2011) ‘Incorporation of bevacizumab in the primary treatment of ovarian cancer’, New England Journal of Medicine, 365(26), pp. 2473–2483.
- Cancer Genome Atlas Research Network (2011) ‘Integrated genomic analyses of ovarian carcinoma’, Nature, 474(7353), pp. 609–615.
- Coleman, R.L., Oza, A.M., Lorusso, D. et al. (2017) ‘Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial’, The Lancet, 390(10106), pp. 1949–1961.
- Colombo, N., Sessa, C., du Bois, A. et al. (2019) ‘ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease’, Annals of Oncology, 30(5), pp. 672–705.
- Goff, B.A., Mandel, L.S., Drescher, C.W. et al. (2007) ‘Development of an ovarian cancer symptom index: possibilities for earlier detection’, Cancer, 109(2), pp. 221–227.
- González-Martín, A., Pothuri, B., Vergote, I. et al. (2019) ‘Niraparib in patients with newly diagnosed advanced ovarian cancer’, New England Journal of Medicine, 381(25), pp. 2391–2402.
- Kurman, R.J. and Shih, I.-M. (2010) ‘The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory’, American Journal of Surgical Pathology, 34(3), pp. 433–443.
- Ledermann, J., Harter, P., Gourley, C. et al. (2012) ‘Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer’, New England Journal of Medicine, 366(15), pp. 1382–1392.
- Mirza, M.R., Monk, B.J., Herrstedt, J. et al. (2016) ‘Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer’, New England Journal of Medicine, 375(22), pp. 2154–2164.
- Moore, K., Colombo, N., Scambia, G. et al. (2018) ‘Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer’, New England Journal of Medicine, 379(26), pp. 2495–2505.
- National Institute for Health and Care Excellence (2011, updated) Ovarian cancer: recognition and initial management (CG122). London: NICE.
- Norquist, B., Harrell, M.I., Brady, M.F. et al. (2016) ‘Inherited mutations in women with ovarian carcinoma’, JAMA Oncology, 2(4), pp. 482–490.
- Prat, J. (2014) ‘Staging classification for cancer of the ovary, fallopian tube, and peritoneum’, International Journal of Gynaecology and Obstetrics, 124(1), pp. 1–5.
- Pujade-Lauraine, E., Hilpert, F., Weber, B. et al. (2014) ‘Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial’, Journal of Clinical Oncology, 32(13), pp. 1302–1308.
- Ray-Coquard, I., Pautier, P., Pignata, S. et al. (2019) ‘Olaparib plus bevacizumab as first-line maintenance in ovarian cancer’, New England Journal of Medicine, 381(25), pp. 2416–2428.
- Sung, H., Ferlay, J., Siegel, R.L. et al. (2021) ‘Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries’, CA: A Cancer Journal for Clinicians, 71(3), pp. 209–249.
- Vergote, I., Tropé, C.G., Amant, F. et al. (2010) ‘Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer’, New England Journal of Medicine, 363(10), pp. 943–953.